Future Planet Capital

Future Planet Capital, based in London, is an impact-led venture capital firm that focuses on investing in high-growth companies addressing global challenges. The firm manages over $400 million in assets and has deployed an additional $200 million through co-investment initiatives. Their investment strategy aligns with the UN Sustainable Development Goals, targeting sectors such as climate change, health, education, security, and sustainable growth. Notable investments by Future Planet Capital include companies like 23andMe, Clarivate Analytics, and Vaccitech, which played a significant role in developing the Oxford-AstraZeneca COVID-19 vaccine. The firm has been instrumental in supporting innovations from top universities and research ecosystems globally, leveraging a data-driven approach to systematically score and benchmark the world's most innovative companies. Future Planet Capital's portfolio includes over 140 companies across various stages and geographies, focusing on impactful solutions like Tokamak Energy for sustainable energy, Captura for carbon removal, and Barinthus Biotherapeutics for advanced vaccines and immunotherapies. The firm is known for its commitment to fostering sustainable and profitable growth through strategic partnerships and deep industry expertise. The firm is led by a seasoned team of professionals, including co-founder and Executive Chairman Douglas Hansen-Luke, who bring a wealth of knowledge in science, innovation, and investment to support and scale their portfolio companies effectively.